<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942354</url>
  </required_header>
  <id_info>
    <org_study_id>PRACTECAL-PRO</org_study_id>
    <nct_id>NCT03942354</nct_id>
  </id_info>
  <brief_title>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</brief_title>
  <acronym>PRACTECAL-PRO</acronym>
  <official_title>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medecins Sans Frontieres, Netherlands</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sussex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>THINK TB &amp; HIV Investigative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wits Health Consortium (Pty) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Public Health, Republic of Belarus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Republic of Uzbekistan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medecins Sans Frontieres, Netherlands</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant&#xD;
      Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient&#xD;
      perspective in terms of their quality of life, shared decision making and satisfaction with&#xD;
      services.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tolerability of drugs for TB is a complex and dynamic course for patients with drug&#xD;
      resistance and can be affected by many different factors. A deeper understanding of the&#xD;
      perspectives and experience of men and women participating in novel TB treatment trials will&#xD;
      add to the understanding of the safety and efficacy of treatment.&#xD;
&#xD;
      TB-PRACTECAL is a multicentre, open label, phase 2-3 randomised controlled trial evaluating&#xD;
      exclusively oral 6 months regimens containing bedaquiline, pretomanid, linezolid +/-&#xD;
      moxifloxacin or clofazimine for the treatment of microbiologically confirmed pulmonary&#xD;
      M/XDR-TB. It is registered with the ClinicalTrials.gov with identifier number NCT02589782.&#xD;
      The trial aims to recruit 630 adults from two sites in Uzbekistan (Nukus and Tashkent) and&#xD;
      one site each from Belarus and South Africa.&#xD;
&#xD;
      The TB-PRACTECAL trial assumes that even if the investigational arms would have non-inferior&#xD;
      efficacy and safety compared to the standard of care outcomes, patients would prefer a&#xD;
      shorter, exclusively oral regimen with a lower pill count. This study therefore aims to&#xD;
      describe patient experiences (i.e. the quality of the treatment experience as opposed to the&#xD;
      quantity of treatment or the amount of time spent on it).&#xD;
&#xD;
      The PRACTECAL-PRO sub-study aims to answer the question: &quot;What are the perceptions,&#xD;
      expectations and experiences of novel TB treatment for adult patients participating in a&#xD;
      six-month regimen clinical trial in Uzbekistan, South Africa and Belarus?&quot;&#xD;
&#xD;
      The objectives for the analysis are:&#xD;
&#xD;
        -  To compare baseline scores between trial patients (all interventional arm patients plus&#xD;
           standard of care patients) with healthy controls.&#xD;
&#xD;
        -  To assess changes in scores over time in patients on the intervention arms and patients&#xD;
           on the standard of care arm.&#xD;
&#xD;
        -  To assess the utility of the SF 12 and SGRQ in a TB clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in St George's respiratory questionnaire SGRQ survey questionnaire from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the quality of life (QoL) of trial patients from baseline to 12 months: both those treated in the investigational arms and the standard of care arm. For the SGRQ, a change of 4 points is suggested to indicate a clinically significant change, although the questionnaire was developed with patients who had COPD rather than TB. In the sub-study with a relatively small sample we cannot be confident about whether a change of 4 points represents a similarly significant change, but we will be mindful to assess this possibility. Ultimate aim is to determine whether disease-specific patient quality of life scores improve in investigational arm patients from baseline to successful completion of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Short form 12 survey questionnaire (patient satisfaction and experience) from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Two summary scores are reported from the SF-12 - a mental component score (MCS-12) and a physical component score (PCS-12). The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). Ultimate aim is to determine whether disease-specific patient satisfaction scores improve in investigational arm patients from baseline to successful completion of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Multidrug Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 72 intervention arm trial patients (from TB-PRACTECAL trial) are anticipated across all three sites: South Africa, Belarus, and Karakalpakstan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>72 standard therapy trial patients (from TB-PRACTECAL trial) will be recruited across all three sites. Patients will complete measures at baseline, 3 months, 6 months and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bedaquiline</intervention_name>
    <description>Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Sirturo</other_name>
    <other_name>R207910</other_name>
    <other_name>TMC207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pretomanid</intervention_name>
    <description>Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>PA-824</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Avelox, BAY 12-8039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
    <description>Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Lamprene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Directly observed therapy (DOT)</intervention_name>
    <description>Standard therapy</description>
    <arm_group_label>Standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients recruited into the TB-PRACTECAL trial in the approved sites OR&#xD;
&#xD;
          -  Local healthy-controls of a similar profile in terms of age and gender aged â‰¥18 years&#xD;
             AND&#xD;
&#xD;
          -  Literate in the study questionnaire languages&#xD;
&#xD;
          -  Able to sign the sub-study informed consent form after agreeing to the additional&#xD;
             interviews and completion of questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TB patients excluded from TB-PRACTECAL clinical trial&#xD;
&#xD;
          -  Healthy volenteers with co-morbidities&#xD;
&#xD;
          -  Healthy volenteers found to have TB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverley Stringer</last_name>
    <role>Principal Investigator</role>
    <affiliation>MSF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola James, MSc</last_name>
    <phone>+44 2070674255</phone>
    <email>nicola.james@london.msf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Batts</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Nshimiyimana, MD</last_name>
      <phone>+375336486008</phone>
      <email>minsk-ct-mtl@oca.msf.org</email>
    </contact>
    <investigator>
      <last_name>Varvara Solodovnikova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doris Goodwin Hospital</name>
      <address>
        <city>Pietermaritzburg</city>
        <state>KwaZulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odette van Amsterdam</last_name>
      <phone>033 398 0054</phone>
      <email>O.Amsterdam@thinksa.org.za</email>
    </contact>
    <investigator>
      <last_name>Ronelle Moodliar, MBBS, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>THINK Clinical Trial Unit, Hillcrest</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>3650</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seshni Moorgas</last_name>
      <phone>0317771009</phone>
      <email>s.moorgas@think.org.za</email>
    </contact>
    <investigator>
      <last_name>Ronelle Moodliar, MBBS,MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen Jospeh Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Motlhako</last_name>
      <phone>+27 11 276 8800</phone>
      <email>smotlhako@witshealth.co.za</email>
    </contact>
    <investigator>
      <last_name>Mohammed Rassool, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Republican TB Hospital No. 2</name>
      <address>
        <city>Nukus</city>
        <state>Karakalpakstan</state>
        <country>Uzbekistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soe Moe, MD</last_name>
      <phone>+998939200344</phone>
      <email>NukusCT-med2@oca.msf.org</email>
    </contact>
    <investigator>
      <last_name>Tigay N Zinaida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital</name>
      <address>
        <city>Tashkent</city>
        <country>Uzbekistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei Sun Aw, MD</last_name>
      <phone>+998 933881121</phone>
      <email>tashkent-crc@oca.msf.org</email>
    </contact>
    <investigator>
      <last_name>Irina Liverko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>South Africa</country>
    <country>Uzbekistan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life, drug-resistant tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Bedaquiline</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

